Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target
$LUCD
Medical/Dental Instruments
Health Care
Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/27/2021 | $16.00 | Buy | Ascendiant Capital |
| 12/15/2021 | $17.00 → $13.00 | Buy | Needham |
| 11/8/2021 | $18.00 | Buy | Canaccord Genuity |
| 11/8/2021 | $14.00 | Buy | BTIG Research |
| 11/8/2021 | $21.00 | Overweight | Cantor Fitzgerald |
| 11/8/2021 | $17.00 | Buy | Needham |
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements. As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing
Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.
LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has entered into its first concierge medicine contract with LEAA Health. The contract provides LEEA Health's membership-based patients access to groundbreaking esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA Test. This expands LEAA Health's enhanced personal
NEW YORK, Feb. 18, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that on February 14, 2025, PAVmed received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the Nasdaq Capital Market's Continued Listing Standards for Primary Equity Securities, and its securities will continue to be listed and traded on The Nasdaq Capital Market.
NEW YORK, Feb. 6, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12 at the Cliff Lodge in Snowbird, UT. Shaun O'Neil, Lucid's President and Chief Operating Officer, will host one-on-one meetings throughout the conference. To schedule a one-on-one meeting, investors are encouraged to
Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor Ongoing initiatives position PAVmed to preserve Nasdaq listing Conference call and webcast to be held today, November 14th at 8:30 AM EST NEW YORK, Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provide
EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13th at 8:30 AM EST NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024.
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 31, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 14, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
3 - Lucid Diagnostics Inc. (0001799011) (Issuer)
4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
SCHEDULE 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)
S-8 - Lucid Diagnostics Inc. (0001799011) (Filer)
S-8 - Lucid Diagnostics Inc. (0001799011) (Filer)
Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00
Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously
Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)
SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)